Exelixis’ drug staves off neuroendocrine tumor progression in broad swath of patients

Lei Lei Wu

News Reporter

BARCELONA — A new treatment option for a wide range of patients diagnosed with neuroendocrine tumors could be approved in April, as final results of …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Exelixis’ drug staves off neuroendocrine tumor progression in broad swath of patients

Lei Lei Wu

News Reporter

Sign up to read this article for free.

Here's what today's Fed rate cut means for biotech, pharma and venture capital

FDA cancels Applied Therapeutics adcomm, shares skyrocket 65%

All of 23andMe's independent board members resign over disagreements with CEO

With few efficacy details, Insilico claims a Phase 2a win in latest AI readout

You bet your life: After I was diagnosed with a rare cancer, I discovered how a small band of physician-scientists ...

Breaking down silos with a new quantitative approach to drug development

Ex­elix­is’ drug staves off neu­roen­docrine tu­mor pro­gres­sion in broad swath of pa­tients

Lei Lei Wu

News Reporter

Sign up to read this article for free.

Here's what to­day's Fed rate cut means for biotech, phar­ma and ven­ture cap­i­tal

FDA can­cels Ap­plied Ther­a­peu­tics ad­comm, shares sky­rock­et 65%

All of 23and­Me's in­de­pen­dent board mem­bers re­sign over dis­agree­ments with CEO

With few ef­fi­ca­cy de­tails, In­sil­i­co claims a Phase 2a win in lat­est AI read­out

You bet your life: Af­ter I was di­ag­nosed with a rare can­cer, I dis­cov­ered how a small band of physi­cian-sci­en­tists ...

Break­ing down si­los with a new quan­ti­ta­tive ap­proach to drug de­vel­op­ment

Exelixis’ drug staves off neuroendocrine tumor progression in broad swath of patients

Here's what today's Fed rate cut means for biotech, pharma and venture capital

FDA cancels Applied Therapeutics adcomm, shares skyrocket 65%

All of 23andMe's independent board members resign over disagreements with CEO

With few efficacy details, Insilico claims a Phase 2a win in latest AI readout

You bet your life: After I was diagnosed with a rare cancer, I discovered how a small band of physician-scientists ...

Breaking down silos with a new quantitative approach to drug development